肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：CTLA-4基因多态性与舒尼替尼治疗透明细胞转移性肾癌患者总生存有关

2018-06-04 MedSci MedSci原创

肾癌舒尼替尼CTLA-4
关注

自从TKI类药物出现后，透明细胞转移性肾细胞癌（cc-mRCC）患者生存得到改善。TKI类药物与免疫反应相互作用。CLIN CANCER RES近期发表了一篇文章，研究免疫检查点基因多态性是否与舒尼替尼治疗的cc-mRCC患者临床结局有关。

自从TKI类药物出现后，透明细胞转移性肾细胞癌（cc-mRCC）患者生存得到改善。TKI类药物与免疫反应相互作用。CLIN CANCER RES近期发表了一篇文章，研究免疫检查点基因多态性是否与舒尼替尼治疗的cc-mRCC患者临床结局有关。

作者在550例舒尼替尼治疗的cc-mRCC患者队列中研究PD-L1，PD-1和CTLA-4的27个单核苷酸多态性（SNP）与无进展生存和总生存之间可能的关系。在138例舒尼替尼治疗的cc-mRCC验证队列中验证显着相关的SNPs。最后，将发现队列和验证队列的数据进行荟萃meta分析。研究结果发现，CTLA4-rs231775和CD274 rs7866740在修正了年龄，性别等因素后在发现队列中与总生存显着相关。在验证队列中，两个SNPs和总生存之间的关系未达到统计学显着意义。meta分析后，CTLA-4 rs231775与总生存显着相关。GG亚型的患者总生存优于AG亚型或AA亚型患者。未发现与无进展生存之间的显着相关性。

文章最后认为，CTLA-4基因的rs231775与舒尼替尼治疗的cc-mRCC患者总生存改善有关，可以用作预后标志。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1386394, encodeId=615e138639426, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455918, encodeId=373e145591840, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461865, encodeId=86fa14618659d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629261, encodeId=7b29162926189, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321809, encodeId=0db532180956, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jun 06 05:37:49 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 1249842em09(暂无昵称)

    #转移性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1386394, encodeId=615e138639426, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455918, encodeId=373e145591840, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461865, encodeId=86fa14618659d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629261, encodeId=7b29162926189, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321809, encodeId=0db532180956, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jun 06 05:37:49 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 zz72

    #细胞转移#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1386394, encodeId=615e138639426, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455918, encodeId=373e145591840, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461865, encodeId=86fa14618659d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629261, encodeId=7b29162926189, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321809, encodeId=0db532180956, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jun 06 05:37:49 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 hywen7328

    #CTLA-4#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1386394, encodeId=615e138639426, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455918, encodeId=373e145591840, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461865, encodeId=86fa14618659d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629261, encodeId=7b29162926189, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321809, encodeId=0db532180956, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jun 06 05:37:49 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 xzw120

    #多态性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1386394, encodeId=615e138639426, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455918, encodeId=373e145591840, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461865, encodeId=86fa14618659d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629261, encodeId=7b29162926189, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jun 06 10:47:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321809, encodeId=0db532180956, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jun 06 05:37:49 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 大爰

    学习了谢谢分享!!

    0

相关资讯

Cell：警惕！癌症的种子在童年就已种下，大部分人可能都有

今日，顶尖学术期刊《细胞》在线刊发了一项关于癌症的最新研究。来自英国的研究人员发现了一个可怕的事实：引起癌症的种子最早在童年就已深植于人体之中。对于这些异常，我们能做的只有祈祷它不要萌芽……

Radiology：肾癌患者的世纪福音！减少腹部脂肪或可提高生存率！

肾癌是泌尿外科常见的恶性肿瘤，发病率占成人恶性肿瘤的2%一3%，全世界发病率每年增加2%，每年死于肾癌的患者近10000例。我们已经知道，肾癌的发病与肥胖有关。而近日，一项新的研究显示，脂肪沉积少的女性肾癌患者比脂肪沉积较多的患者存活时间更长。

辉瑞酪氨酸激酶抑制剂Inlyta治疗早期肾癌的临床三期试验惨遭失败

一项ATLAS临床III期试验评估了Inlyta作为肾切除术后复发性肾细胞癌（RCC）高危患者辅助治疗的潜力。独立的数据监测委员会进行分析后发现，以延长无病生存期（DFS）为终点，与安慰剂组相比，Inlyta治疗组患者并没有明显改善。

关注｜CSCO肾癌诊治指南新版发布，五大亮点等你来看！

CSCO中国肾癌诊治指南2018版推荐： ☆ 卡博替尼用于中高危晚期肾癌的一线治疗 ☆ 免疫联合治疗作为肾癌晚期一线治疗方式 ☆ 靶向药物与免疫治疗的联合作为晚期肾癌的二线治疗 ☆ 疾病分层将成为晚期肾癌的治疗策略

NCCN临床实践指南：肾癌（2018.V4）

2018年4月，美国国家综合癌症网络(NCCN)发布了肾癌指南2018年第4版，指南主要内容包括： 指南更新摘要 初始检查 Ⅰ-Ⅲ期疾病初始治疗和随访 Ⅳ期疾病的初始治疗 透明细胞组织学一线治疗和辅助治疗 非透明的细胞组织学系统治疗 手术治疗原则 随访 直接治疗风险模型

Sci Rep：肾脏癌中，免疫和上皮间质转化关系表明了潜在的治疗靶标和预后评估方法

上皮间质转化（EMT）和免疫调控在恶性肿瘤中均为重要的生物学过程。最近，有研究人员综合性的探索了上皮间质转化特性和免疫检查点特性之间的关系，并且探索了两者关系在预测透明细胞肾细胞癌（ccRCC）患者预后中的作用。研究人员从一个基于实验的研究中搜集了EMT相关的基因，并利用癌症基因组数据库对上述基因进行了调查。研究总共包括了357个基因，其中23个表达上调和与预后相关的基因在ccRCC中被进一步分析